Company intelligence / Profile preview
ContraFect Corporation
Yonkers, New York, United States
- Ownership
- Public · CFRX
- Development stage
- Other
01
Overview
ContraFect's lead drug candidate exebacase failed to meet primary endpoints in Phase 3 clinical trials. The company filed for Chapter 7 bankruptcy on December 4, 2023. Assets were sold to Aurobac Therapeutics SAS in March 2024.
- Therapeutic areas
- CardiovascularInfectious Diseases
- Modalities
- Direct Lytic Agents (DLAs)lysinsamurin peptidesenzymesmonoclonal antibodiesbacteriophage therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaboration with a leading hospital in Lyon, France
Beyond the preview
Go deeper on ContraFect Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ContraFect Corporation.